Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    mrx34
Show Display Options
Rank Status Study
1 Withdrawn Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions
Condition: Melanoma
Interventions: Drug: MRX34;   Drug: Dexamethasone
2 Terminated A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Conditions: Primary Liver Cancer;   SCLC;   Lymphoma;   Melanoma;   Multiple Myeloma;   Renal Cell Carcinoma;   NSCLC
Intervention: Drug: MRX34

Indicates status has not been verified in more than two years